Skip to content

Efficacy and Safety Analysis of Stereotactic Body Radiotherapy (SBRT) for Elderly Patients with Small Hepatocellular Carcinoma: A Bidirectional Observational Study

Efficacy and Safety Analysis of Stereotactic Body Radiotherapy (SBRT) for Elderly Patients with Small Hepatocellular Carcinoma: A Bidirectional Observational Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600129435
Enrollment
Unknown
Registered
2026-08-04
Start date
2026-08-10
Completion date
Unknown
Last updated
2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma (HCC)

Interventions

Observation Group ( Stereotactic Body Radiotherapy ):None

Sponsors

Southern Medical University Southern Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
70 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Voluntarily participate in this study and sign the informed consent form; 2. Aged >=70 years old, regardless of gender; 3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0–2; 4. Diagnosed with primary hepatocellular carcinoma (HCC) by pathological examination or clinical criteria, meeting the definition of small hepatocellular carcinoma; 5. Unsuitable for or refuse surgical resection, local ablation or liver transplantation, including but not limited to advanced age, severe comorbidities (cardiac, pulmonary, renal diseases, etc.), high-risk tumor location, poor liver functional reserve, and patient refusal of invasive treatment; 6. Child-Pugh liver function score <=7 (Class A or B); 7. Planned to receive stereotactic body radiotherapy (SBRT) with curative intent (not palliative); 8. Have at least one measurable lesion assessed per the modified Response Evaluation Criteria in Solid Tumors (mRECIST); 9. Satisfactory function of major organs.

Exclusion criteria

Exclusion criteria: 1.Prior radiotherapy, ablation, surgery or transarterial chemoembolization (TACE) targeting the index lesion; 2.Presence of extrahepatic metastasis or vascular invasion (tumor thrombus in portal vein, hepatic vein or inferior vena cava); 3.Diffuse hepatocellular carcinoma or intrahepatic tumor burden exceeding the up-to-7 criterion; 4.Child-Pugh liver function score >= 8 (advanced Class B or Class C); 5.Any condition that may interfere with study results or endanger subject safety, as judged by the investigator.

Design outcomes

Primary

MeasureTime frame
Freedom from Local Progression;

Secondary

MeasureTime frame
PFS(Progression-Free Survival);Treatment-related adverse event(TRAE);OS(Overall Survival);ORR(Objective Response Rate);

Countries

China

Contacts

Public ContactZhang Yuqin

Southern Medical University Southern Hospital

7913969631@qq.com+86 20 61642136

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 25, 2026